Blog
Peptide research, protocols, and community insights.
Endocrinologists Graded the Growth Hormone Peptides. Three Got the Bottom Tier.
A 2026 review in Frontiers in Endocrinology sorted the growth hormone peptides by how much human evi…
Three Recalls, Three Pharmacies, One Ingredient
A third Texas compounding pharmacy has recalled injectable products over elevated endotoxin levels,…
Semaglutide Improved Alzheimer's Biomarkers and Did Nothing for Patients
Two trials gave oral semaglutide to 3,808 people with early Alzheimer's disease for two years. The b…
Two GLP-1 Drugs Finally Went Head to Head on Heart Attacks. It Was a Tie.
The FDA has approved tirzepatide to reduce the risk of heart attacks and strokes in people with type…
SS-31 Is an Approved Drug Now. Just Not for What It Is Sold For.
SS-31, better known in the longevity world as a mitochondrial anti-aging peptide, became an FDA appr…
Sports Medicine Doctors Reviewed 565 Peptide Studies. Their Verdict: The Evidence Is Not There.
A UCLA team reviewed 565 studies on six of the most popular unapproved peptides and related compound…
The Safety Net Under Compounded Drugs Has Some Large Holes
A study in the Journal of the American Pharmacists Association looked at newly registered compoundin…
Eighteen Vials of Counterfeit Retatrutide Went to a Lab. One Matched Its Label.
An Australian laboratory tested 18 counterfeit retatrutide samples. Only one contained what the labe…
Sterile Is Not the Same as Safe: A Recall Worth Understanding
A compounding pharmacy recalled three lots of injectable peptide over high endotoxin levels after pa…
A Peptide Seller Got Six Years, and the Lab Certificates Were Forged
A peptide company owner was sentenced to 70 months in federal prison for selling unapproved drugs wi…
Three Gut Peptides, Ranked by Evidence Instead of Hype
BPC-157, KPV, and larazotide are the three peptides sold hardest for gut problems. Ranked by how muc…
The One Peptide the FDA Panel Turned Down
Seven peptides went before the FDA advisory committee in July. Six were recommended for compounding.…
The Obesity Nobody Chose, and the First Drug That Treats It
Some people develop relentless hunger after a brain tumor damages the part of the brain that control…
The Vial Problem: Why Compounded GLP-1s Keep Causing Overdoses
US regulators have logged more than 1,700 adverse event reports tied to compounded semaglutide and t…
The Biggest Review of Skin Peptides Yet, and What It Found
Researchers pooled 19 randomized trials covering 1,341 people to ask whether peptides actually do an…
A Weight Loss Drug Just Cut Knee Pain by 75 Percent
Retatrutide produced 28.7 percent average weight loss in its first Phase 3 obesity trial, the highes…
After GLP-1: Why Every Big Drugmaker Is Now Chasing Amylin
Novo Nordisk, Eli Lilly, Roche, and Amgen are all running trials on a second appetite hormone called…
An FDA Panel Just Voted to Let Pharmacies Make Six Peptides
On July 23, 2026, an FDA advisory committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax,…
The First GLP-1 Pill You Can Take Any Time: Lilly's Foundayo Is Here
On April 1, 2026, the FDA approved Foundayo, a daily weight loss pill from Eli Lilly. It is the firs…
BPC-157 and TB-500: Why the Healing Hype Is Running Ahead of the Proof
BPC-157 and TB-500 are pitched online as near-magic fixes for injured tendons, joints, and guts. But…